Vanguard Group Inc Oncorus, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.28 - $0.45 $5,759 - $9,255	-20,568 Reduced 4.15%	475,345 $161,000
Q4 2022 Feb 10, 2023	SELL	$0.24 - $0.76 $96 - $304	-401 Reduced 0.08%	495,913 $123,000
Q3 2022 Nov 14, 2022	SELL	$0.85 - $1.65 $47,877 - $92,937	-56,326 Reduced 10.19%	496,314 $422,000
Q2 2022 Aug 12, 2022	SELL	$1.04 - $1.86 $35,328 - $63,184	-33,970 Reduced 5.79%	552,640 $696,000
Q1 2022 May 13, 2022	SELL	$1.44 - $5.62 $466,905 - $1.82 Million	-324,240 Reduced 35.6%	586,610 $1.05 Million
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $693,606 - $1.6 Million	137,894 Added 17.84%	910,850 $4.8 Million
Q3 2021 Nov 12, 2021	BUY	$9.29 - $14.27 $1.02 Million - $1.56 Million	109,287 Added 16.47%	772,956 $7.22 Million
Q2 2021 Aug 13, 2021	BUY	$13.3 - $17.3 $8.83 Million - $11.5 Million	663,669 New	663,669 $9.16 Million

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.